GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,600 ($21.26) price objective by research analysts at UBS AG in a research report issued to clients and investors on Monday, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the stock. UBS AG’s price objective would indicate a potential upside of 5.02% from the stock’s previous close.

A number of other analysts also recently weighed in on GSK. Deutsche Bank AG reiterated a “hold” rating and set a GBX 1,720 ($22.85) price target on shares of GlaxoSmithKline plc in a report on Friday, June 30th. J P Morgan Chase & Co reiterated a “neutral” rating and set a GBX 1,750 ($23.25) price target on shares of GlaxoSmithKline plc in a report on Friday, June 30th. Barclays PLC reiterated an “equal weight” rating and set a GBX 1,550 ($20.60) price target on shares of GlaxoSmithKline plc in a report on Monday, July 3rd. Citigroup Inc. downgraded GlaxoSmithKline plc from a “buy” rating to a “neutral” rating and set a GBX 1,700 ($22.59) price target for the company. in a report on Wednesday, July 5th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a GBX 1,900 ($25.25) price target on shares of GlaxoSmithKline plc in a report on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the company’s stock. GlaxoSmithKline plc currently has an average rating of “Hold” and an average target price of GBX 1,676 ($22.27).

GlaxoSmithKline plc (GSK) traded down 0.241% on Monday, reaching GBX 1519.835. The company’s stock had a trading volume of 3,214,272 shares. GlaxoSmithKline plc has a 52-week low of GBX 1,444.00 and a 52-week high of GBX 1,724.50. The firm’s 50-day moving average price is GBX 1,502.15 and its 200-day moving average price is GBX 1,580.48. The stock’s market cap is GBX 74.29 billion.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline plc (GSK) Given a GBX 1,600 Price Target at UBS AG” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/23/glaxosmithkline-plc-gsk-given-a-gbx-1600-price-target-at-ubs-ag.html.

In related news, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction on Wednesday, July 26th. The stock was acquired at an average price of GBX 1,599 ($21.25) per share, for a total transaction of £36,249.33 ($48,165.47). Also, insider Simon Dingemans purchased 1,076 shares of the business’s stock in a transaction on Thursday, October 12th. The shares were bought at an average price of GBX 1,527 ($20.29) per share, with a total value of £16,430.52 ($21,831.68). Insiders have acquired a total of 3,368 shares of company stock valued at $5,305,807 in the last quarter.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.